NASDAQ$FDMT
4D Molecular Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported first quarter 2023 financial results and provided operational highlights.
4D Molecular Therapeutics reported positive interim data from the PRISM clinical trial, acquired rights to sCFH, and closed an upsized public offering, with cash expected to fund operations into the first half of 2026.
- Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet AMD at the 2023 ARVO Annual Meeting.
- On track for completion of enrollment of the Phase 2 Dose Expansion Stage of the PRISM clinical trial in Q3 2023.
- Acquired all worldwide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc. and announced sCFH as payload for 4D-175 lead product candidate for geographic atrophy (GA).
- Closed upsized public offering of common stock including full exercise of underwriters’ option to purchase additional shares with total net proceeds of approximately $129 million.
Headline financials
Revenue & EPS history
4DMT · Revenue · Quarterly
$298K
Revenue by segment
4DMT · $20.2M total across 1 segment · Q3 2023
- Collaboration & license rev.$20.2M+3940.8%100.0%
Forward guidance
4D Molecular Therapeutics expects several milestones, including completion of enrollment for the 4D-150 Phase 2 PRISM trial in Q3 2023, initial interim data for 4D-150 in wet AMD and DME in H1 2024, and an update on the 4D-175 program in Q4 2023, and cash and cash equivalents, inclusive of net proceeds from the May 2023 offering, to be sufficient to fund operations into the first half of half of 2026.
Tailwinds
- Enrollment of the Phase 2 randomized Dose Expansion stage of the PRISM clinical trial expected to complete in Q3 2023
- Initial interim 4D-150 for wet AMD Phase 2 data expected in H1 2024
- Enrollment of the Phase 2 SPECTRA clinical trial for DME expected to begin in Q3 2023
- Initial interim 4D-150 for DME Phase 2 data expected in H1 2024
- Program update expected in Q4 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+8.5%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+20.0%
Q3 2022
Best reaction
-10.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.6% | -0.7% | -17.3% | |
| Q4 2025 | +7.3% | +7.2% | +22.5% | |
| Q3 2025 | +6.7% | +6.1% | +7.4% | |
| Q1 2025 | +9.9% | +4.7% | +27.0% | |
| Q4 2024 | -8.6% | -8.6% | -28.7% | |
| Q3 2024 | +1.9% | +5.7% | -17.4% | |
| Q2 2024 | +0.6% | +1.6% | +2.4% | |
| Q1 2024 | -2.4% | -2.2% | -13.7% | |
| Q4 2023 | +5.3% | -3.0% | +14.2% | |
| Q3 2023 | +1.8% | +2.2% | +37.7% | |
| Q2 2023 | -1.6% | -1.1% | -7.4% | |
| Q1 2023 | -2.5% | +2.8% | +26.8% | |
| Q4 2022 | -0.7% | -5.4% | -12.5% | |
| Q3 2022 | +20.0% | +66.3% | +188.5% | |
| Q2 2022 | -10.4% | -12.5% | -14.9% | |
| Q1 2022 | -3.1% | -12.9% | -31.5% | |
| Q4 2021 | +8.1% | +1.6% | -22.5% | |
| Q3 2021 | -0.7% | -3.8% | -12.1% | |
| Q2 2021 | -4.0% | +5.2% | +19.4% | |
| Q1 2021 | -3.9% | -3.4% | +2.6% | |
| Q2 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro